Original Article

Progesterone receptor inhibits the proliferation and invasion of endometrial cancer cells by up regulating Krüppel-like factor 9

Xiaofang Yan\textsuperscript{1,2#}, Huilin Zhang\textsuperscript{1,3#}, Jieqi Ke\textsuperscript{1}, Yongli Zhang\textsuperscript{4}, Chenyun Dai\textsuperscript{5}, Mei Zhu\textsuperscript{5}, Feizhou Jiang\textsuperscript{6}, Hongdi Zhu\textsuperscript{2}, Ling Zhang\textsuperscript{2}, Xin Zuo\textsuperscript{2}, Weiling Li\textsuperscript{2}, Xiufeng Yin\textsuperscript{2}, Xiaoping Wan\textsuperscript{1,4}

\textsuperscript{1}Department of Obstetrics and Gynecology, Shanghai General Hospital of Nanjing Medical University, Shanghai 200000, China; \textsuperscript{2}Department of Gynecology and Obstetrics, Yixing People’s Hospital, Yixing 214200, China; \textsuperscript{3}Department of Obstetrics and Gynecology, Women’s Hospital of Nanjing Medical University, Nanjing Maternity and Child Health Care Hospital, Nanjing 210000, China; \textsuperscript{4}Department of Obstetrics and Gynecology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai 200080, China; \textsuperscript{5}Department of Translation Medicine, Shanghai First People’s Hospital Affiliated to Shanghai Jiao Tong University, Shanghai 210000, China; \textsuperscript{6}Department of Obstetrics and Gynecology, the First Affiliated Hospital of Soochow University, Suzhou 215000, China

Contributions: (I) Conception and design: X Wan; (II) Administrative support: X Yan, H Zhang; (III) Provision of study materials or patients: X Yan, H Zhang, J Ke, Y Zhang, C Dai, M Zhu, F Jiang; (IV) Collection and assembly of data: X Yan, H Zhu, L Zhang, X Zuo, W Li, X Yin; (V) Data analysis and interpretation: X Yan, H Zhang, J Ke, Y Zhang, C Dai; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

*These authors contributed equally to this work.

Correspondence to: Xiaoping Wan. Department of Obstetrics and Gynecology, Shanghai General Hospital of Nanjing Medical University, Shanghai 200000, China; Department of Obstetrics and Gynecology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai 200080, China. Email: 15961503212@163.com.

\textbf{Background:} Krüppel-like factor 9 (KLF9) is one of the most important members of the KLF family, and is abnormally expressed in many tumors. However, the detailed function of KLF9 in endometrial cancer (EC) was barely investigated.

\textbf{Methods:} In this study, a total of 52 paired EC tissues were recruited to detect the KLF9 expression. Then a serial of phenotypic experiments and mechanism researches were performed.

\textbf{Results:} The results showed that KLF9 expression was decreased in EC tissues, and the reduced expression of KLF9 is associated with highly metastatic capacity of EC cells. KLF9 could inhibit the proliferation and invasion of EC cells by inhibiting the Wnt/β-catenin signaling pathway. Progesterone receptor (PR) could bind to KLF9 promoter and a positive correlation between KLF9 and PR expression was witnessed.

\textbf{Conclusions:} Taken together, the reduction of KLF9 induced by PR might participate in the development of EC and targeting KLF9 may provide a novel strategy for EC management.

\textbf{Keywords:} Endometrial carcinoma; Krüppel-like factor 9 (KLF9); progesterone receptor (PR); proliferation; invasion

Submitted Nov 02, 2019. Accepted for publication Jan 10, 2020.
doi: 10.21037/tcr.2020.03.53

View this article at: http://dx.doi.org/10.21037/tcr.2020.03.53

Introduction

Endometrial cancer (EC) is one of the most common genital malignancies in women (1). With the development of society and economy and the change of life style, the incidence is increasing rapidly worldwide (2). The prognosis of EC, even in the early stage, is poor, let alone those patients with either advanced stage at diagnosis or recurrent disease following treatment (3). The molecular mechanisms of development of EC are not fully understood. Although many oncogenes and tumor suppressors have been identified as key players underlying tumorigenesis of EC (4-6), however, almost no commonly-accepted biomarkers have been established to facilitate the comprehensive
management of EC patients. Therefore, understanding the molecular events underlying endometrial carcinogenesis and identifying new biomarkers and therapeutic targets will be important.

Krüppel-like factor 9 (KLF9), also known as basic transcription element binding protein 1 (BTEB1), belongs to large KLF transcription factor family, which consists of 17 members (7). KLF9 is expressed in various tissues, most abundantly in the brain, kidney, lung, and testis. KLF9 is also involved in various biological processes such as cell proliferation, differentiation, and neural development (8,9). Recently, KLF9 has emerged as a regulator of oncogenesis and reported to play critical roles in several types of tumor. For example, KLF9 was found to be down-regulated in human colorectal cancer, breast cancer, ovarian cancer, glioblastoma, and hepatocellular cancer and was considered as a tumor suppressor (10-13). The downregulation of KLF9 is associated with tumorigenesis, metastasis, and apoptosis resistance (14,15). However, the possibility that KLF9 is a suppressor of endometrial tumorigenesis in the colon has not been evaluated.

In the present study, we illustrated that KLF9 was downregulated in EC tissues, and its expression was associated with EC cell proliferation and metastasis. We also showed that KLF9 reduced EC cell proliferation and invasion by inhibiting β-catenin signaling activity. Furthermore, we demonstrated that decreased progesterone receptor (PR) was responsible for the downregulation of KLF9 in EC cells.

Methods

Cell culture

Four EC cell lines (RL-95-2, Ishikawa, HEC-1A and KLE) were purchased from the American Type Culture Collection (ATCC). Cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) or DMEM/F12 supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin (Sigma-Aldrich Co, St Louis, MO, USA) and 100 U/mL streptomycin (Sigma-Aldrich) in humidified air at 37 °C with 5% CO₂.

Tissue samples collection

A total of 52 EC specimens were obtained from the Department of Obstetrics and Gynecology, Shanghai General Hospital of Nanjing Medical University and the Department of Obstetrics and Gynecology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University. The clinical data of the patients were collected from the medical records, including gender, age, pathological subtype, lymph node metastasis, etc. The study protocol was approved by Research Ethics Committee of Nanjing Medical University.

RNA extraction and quantitative real-time PCR assay

Total RNA was extracted from 52 EC specimens using Trizol reagent (Invitrogen). The primers of KLF9 were as follows: 5’-AAC TGC TTT TCC CCA GTG TG-3’ (forward) and 5’-TCC CAT CTC AAA GCC CAT TA-3’ (reverse). The following protocol was described previously (16).

Western blot assay

Anti-KLF9 antibody (ab26074, Abcam, Cambridge, MA, USA), anti-β-catenin antibody (ab32572), anti-CCND1 antibody (ab16663), anti-C-myc antibody (ab32072) and anti-GAPDH antibody (ab181602) were all purchased from Abcam Co., Ltd. The detailed protocol was described previously (17).

Construction of overexpression and knockdown model

The overexpression and short-hairpin RNA (shRNA)-mediated knockdown lentivirus plasmids and packaging vectors were prepared as previously described (18). For overexpression model, cells were infected with lentivirus expressing KLF9 (OE-KLF9)/negative control (OE-Control), β-catenin (OE-β-catenin)/negative control (OE-β-Control), PR (OE-PR)/negative control (OE-PR-Control). Full-length of cDNA was inserted into the lentivirus pLenti-EGFP-P2A-Puro-CMV-MCS vector (Obio Technology, Co., Ltd, Shanghai, China). shRNA targeting KLF9 (sh-KLF9) or scrambled shRNA (sh-KLF9-Control) were cloned into pLKD-CMV-G&PR-U6-shRNA (Obio Technology). The sequences used for sh-KLF9 was 5’-GCT TGT TGG ACC TGA ACA AGT-3’. All of these plasmids were confirmed by DNA sequencing. Co-transfection of OE-KLF9 together with OE-β-catenin or OE-β-Control, co-transfection of OE-PR or OE-PR-Control together with sh-KLF9 or sh-KLF9-Control were performed as described.
previously (19).

**Cell proliferation, clone formation and transwell assays**

Cell Counting Kit-8 (CCK8), clone formation and transwell assays were performed in to detect the malignant behaviors of KLF9, including its effects on cell proliferation and invasion, as described previously (20).

**Tumor formation assay in xenograft model**

For the subcutaneous xenograft model, 5-week-old female athymic BALB/c mice were injected subcutaneously with 2×10^7 tumor cells in 100 mL phosphate buffer saline (PBS). Tumor volumes were examined every 2 days when the implantations were starting to grow bigger. Sixteen days after injection, the mice were killed and the primary tumors were excised.

**Luciferase reporter assay**

For TOPFLASH assay: cells were seeded in 12-well plates and co-transfected with TOPFLASH reporter and KLF9 expression vector or control vector on the following day. For KLF9-luciferase assay: cells were seeded in 12-well plates and co-transfected with KLF9-promoter reporter, pRL-SV40 Renilla luciferase reporter vector, and PR expression plasmid or control plasmid. Firefly luciferase activity, normalized to Renilla luciferase activity, was measured 48 h after transfection by the Dual Luciferase Assay System (Promega, Madison, USA).

**Chromatin immunoprecipitation (ChIP) assay**

ChIP assay was performed using the ChIP assay kit according to the instruction (Millipore, USA). Anti-PR was obtained from Abcam (ab2765, Abcam). The input genomic DNA and the immunoprecipitated DNA was amplified by PCR. The PCR products were subjected to gel electrophoresis.

**Immunohistochemistry (IHC) analysis**

Fifty-two EC tumor samples were immunostained with KLF9 and PR antibodies. The IHC procedure and scoring of protein expression were performed as previously described (21). Tissue microarray sections were incubated with primary polyclonal rabbit anti-KLF9 antibody (ab26074, Abcam) and monoclonal mouse anti-PR antibody (ab2765, Abcam) overnight at 4 °C, followed by incubation with biotinylated anti-rabbit and anti-mouse secondary antibody at 37 °C for 30 min respectively. Sections were then incubated with a streptavidin-horseradish peroxidase complex, colorized with 3,3-diaminobenzidine (DAB) chromogen solution and counterstained with hematoxylin. Results were analyzed as previously described. Briefly, the percentage of KLF9 and PR positive cells was scored as follows: 0 for 0%, 1 for 1–33%, 2 for 34–66% and 3 for 67–100%. The intensity of KLF9 and PR staining was also scored as follows: 0 for negative staining, 1 for yellow color staining, 2 for light brown color staining and 3 for brown color staining. The product of the staining intensity and percentage gave rise to the IHC score (IHS). The final results of IHC analysis were defined using a two level system following the IHS: <4 indicates low expression, while 4–12 indicates high expression. Negative controls were employed by replacement of the primary antibody with PBS.

**Statistical analysis**

All experiments were repeated three times. All statistical analyses were performed using SPSS 20.0 software (IBM, SPSS, USA). The statistical differences between groups were determined by t-test or χ^2 test. P<0.05 was considered to be statistically significant.

**Results**

**KLF9 is down-regulated in EC tissue samples**

The KLF9 expression was detected in 52 paired EC tissue samples and corresponding noncancerous tissue samples by real time PCR test. **Figure 1A** showed that the expression levels of KLF9 were significantly decreased in EC tissues than those in noncancerous tissues (P<0.01). Moreover, the detailed relationships between KLF9 expression status and clinicopathological variables were shown in **Table 1**. Noticeably, lower KLF9 expression was significantly correlated with myometrial invasion (P=0.000), lymph node metastasis (P=0.002), and distant metastasis (P=0.026).

**Construction of overexpression model in cell lines**

As is shown in **Figure 1B**, differential expression of KLF9 was detected in EC cell lines. Then we chose Ishikawa and...
HEC-1A cells to construct OE-KLF9 model and the result demonstrated the effectiveness of OE-KLF9 model in Ishikawa and HEC-1A cells (Figure 1C). Similarly, OE-β-catenin and OE-PR models were also successfully prepared in Ishikawa cell (Figure 1D,E).

**OE-KLF9 inhibits EC cell development in vitro and in vivo**

In vitro, CCK8, clone formation and transwell assays remarkably illustrated that OE-KLF9 inhibits EC cell proliferation and invasion (Figure 2A,B,C). Furthermore, the role of KLF9 in tumor development was also explored in vivo. As shown in Figure 2D, compared with OE-Control group, the OE-KLF9 group developed significantly smaller xenograft tumors.

**KLF9 inhibits β-catenin expression**

It was reported that KLF9 could inhibit β-catenin activity and β-catenin signaling is a well-known oncogenic pathway in cancer development (22-24), we highly wondered that whether KLF9 could inhibit cell proliferation and invasion by regulating β-catenin pathway in EC. We firstly conducted TOPFlash luciferase reporter assay in EC cells. Cells were transfected with the TOPFlash reporter, which directly detected β-catenin activity, together with OE-KLF9 or OE-Control. As shown in Figure 2E, OE-KLF9 decreased TOPFlash reporter activity. Furthermore, as the Wnt/β-catenin pathway readouts and β-catenin response elements, the expression of C-Myc and CCND1 were detected. Indeed, similarly to TOPFlash activity, C-Myc and CCND1 expression were significantly decreased in OE-KLF9 cells (Figure 2F). Then we addressed whether β-catenin pathway was involved in KLF9-mediated attenuated proliferation and invasion. EC cells were co-transfected with OE-KLF9 together with OE-β-catenin or OE-β-Control. Clone formation assay and transwell assay were conducted again to test cell proliferation and invasion ability. The results showed that OE-β-catenin partly restrained the effect of OE-KLF9 and restored cell proliferation and invasion ability (Figure 2G,H).

Figure 1 KLF9 expression and construction of the overexpression model of KLF9 (OE-KLF9), β-catenin (OE-β-catenin) and progesterone receptor (OE-PR). (A) The expression levels of KLF9 were significantly decreased in EC tissues than those in noncancerous tissues. (B) Differential expression of KLF9 was detected in EC cell lines. Positive KLF9 expression was witnessed in Ishikawa and HEC-1A cell lines. (C) Successful construction of the KLF9-overexpression model (OE-KLF9) in Ishikawa and HEC-1A cell lines. (D,E) β-catenin-overexpression model (OE-β-catenin) and progesterone receptor-overexpression model (OE-PR) were also successfully prepared in Ishikawa cell line. *, P<0.01. KLF9, Krüppel-like factor 9.
PR could bind to KLF9 promoter to positively regulate KLF9 expression

PR is a well-known transcription factor, regulating target gene expression by binding to a specific sequence within the promoter (25). Bioinformatics analysis revealed that KLF9 promoter contains potential PR binding sequence (Figure 3A). Therefore, we proposed whether PR could activate KLF9 expression. Firstly, we constructed luciferase reporter vector containing KLF9 promoter sequence. Then Ishikawa cells were co-transfected with reporter plasmid and OE-PR or OE-PR-Control. Figure 3B showed that OE-PR significantly increased the KLF9 reporter gene activity. Consistently, PCR and western blot assays further proved that the cellular mRNA and protein levels of KLF9 were elevated by OE-PR (Figure 3C,D). Then ChIP assay was performed to determine whether PR could regulate KLF9 by binding to its promoter. As indicated in Figure 3E, the KLF9 promoter region was specifically immunoprecipitated with anti-PR antibody, indicating that PR bound to KLF9 promoter. These findings strongly suggest that PR could activate KLF9 expression by directly binding to its promoter. The notion was further supported by the positive correlation between KLF9 and PR expression (P=0.031) detected by IHC analysis in 52 EC tissue samples (Figure 3F, Table 2).

KLF9 mediated PR-induced tumor suppressor in EC

We next investigated whether KLF9 is functionally important in PR-induced phenotypic alterations in EC. sh-KLF9 model was confirmed by western blot assay in Ishikawa cell line (Figure 4A). Then Ishikawa cell was co-transfected with OE-PR together with sh-KLF9 or sh-KLF9-Control. The CCK8 assay and clone formation assay showed that sh-KLF9 partly abrogated the reduction of proliferation ability caused by ectopic expression of PR (Figure 4B,C). The cell invasion assay demonstrated that sh-KLF9 partly restrained the effect of OE-PR (Figure 4D). These results remarkably indicated that KLF9 was an important downstream target gene of PR and involved in PR-induced tumor suppressor effect in EC.

Discussion

Recently, the role of KLF9 in regulating tumorigenesis...
Figure 2 OE-KLF9 inhibits EC cell development and KLF9 suppresses β-catenin expression. (A,B,C) CCK8, colony formation and transwell assays were performed to determine cell viability and cell proliferation ability. Specifically, CCK8 test showed that OE-KLF9 (upper line) significantly inhibited cell proliferation in Ishikawa and HEC-1A cell line in comparison with OE-control group (lower line) (A). Colony formation assay demonstrated that compared with OE-control group (left lane), OE-KLF9 (right lane) significantly inhibited cell proliferation in Ishikawa and HEC-1A cell line (B). Similarly, transwell assay illustrated that OE-KLF9 (right lane) group also dramatically suppressed cell invasion compared with that of in OE-control group (left lane) in Ishikawa and HEC-1A cell line (C). (D) Xenograft tumors were constructed and measured. (E) β-catenin activity was measured by Topflash luciferase reporter assay. (F) Western blot assays were performed to detect the expression levels of KLF9, β-catenin, C-myc, and CCND1. (G,H) Colony formation and transwell assays were performed to detect cell proliferation and invasion ability of cells co-transfected with OE-KLF9 together with OE-β-catenin or OE-β-control vector. For colony formation assay, compared with OE-β-control, OE-β-catenin partly restrained the effect of OE-KLF9 and restored cell proliferation (left picture). For transwell assays, OE-β-catenin partly also sustained the effect of OE-KLF9 and restored cell invasion ability. *, P<0.05. KLF9, Krüppel-like factor 9; EC, endometrial cancer.
and progression has been recognized in several cancers. However, the detailed function of KLF9 in human EC is not fully understood. In this present study, we firstly investigated KLF9 expression in EC tissues and cell lines. We found that KLF9 was decreased in EC tissues, and reduced KLF9 expression was associated with highly metastatic capacity of EC cells. We also showed that KLF9 could reduce EC cell proliferation and invasion by inhibiting β-catenin signaling activity. Besides, we demonstrated that decreased PR was associated with the downregulation of KLF9 in EC cells.

The development and progression of EC is influenced by many factors. For example, FKBP51 is significantly decreased in endometrial carcinoma and could reduce cell

Figure 3 PR could bind to KLF9 promoter to positively regulate KLF9 expression. (A) Luciferase reporter assay showed that overexpression of PR enhanced the promoter activity of KLF9. (B) OE-PR significantly increased the KLF9 reporter gene activity. (C, D) PCR and western blot assays proved that the cellular mRNA and protein levels of KLF9 were elevated by OE-PR. (E) ChIP assay revealed that KLF9 promoter was immunoprecipitated with PR antibody. (F) Representative IHC staining pictures of PR and KLF9 in EC tissues. The upper panel represented the weak positive staining and the lower panel represented the strong positive staining. *, P<0.05. KLF9, Krüppel-like factor 9; PR, progesterone receptor; IHC, immunohistochemistry; EC, endometrial cancer.
proliferation and increase the sensitivity of progesterone treatment by inhibiting the Akt pathway (26). The increased expression of Notch2 induced by abnormal miR-181c is closely related to the recurrence of EC (27). Our results indicate a new tumor suppressor of EC. We showed that KLF9 is significantly decreased in EC tissues, and could inhibit cell proliferation, metastasis, and tumorigenesis in vitro and in vivo. Our findings provide a new potential biomarker and target for the diagnosis and treatment of EC.

To explore the mechanisms of KLF9 in EC, we firstly

Table 2 Positive correlation between KLF9 and PR expression detected by IHC analysis in 52 EC tissue samples

<table>
<thead>
<tr>
<th>Parameter</th>
<th>No.</th>
<th>PR expression</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Low (%)</td>
<td>High (%)</td>
</tr>
<tr>
<td>KLF9 Low</td>
<td>28</td>
<td>22 (78.57)</td>
<td>6 (21.43)</td>
</tr>
<tr>
<td>KLF9 High</td>
<td>24</td>
<td>12 (50.00)</td>
<td>12 (50.00)</td>
</tr>
</tbody>
</table>

*, P<0.05. KLF9, Krüppel-like factor 9; PR, progesterone receptor; IHC, immunohistochemistry; EC, endometrial cancer.

**Figure 4** KLF9 mediated PR-induced tumor suppressor in EC. (A) sh-KLF9 model was confirmed by western blot assay in Ishikawa cell line. (B,C) The CCK8 assay and clone formation assay showed that sh-KLF9 partly abrogated the reduction of proliferation ability caused by ectopic expression of PR after Ishikawa cell was co-transfected with OEP-PR together with sh-KLF9 or sh-KLF9-Control. For CCK8 assay, compared with sh-KLF9-Control (green line), sh-KLF9 (blue line) partly abrogated the reduction of proliferation ability caused by ectopic expression of PR (B). For clone formation assay, sh-KLF9 (right lane) also revoked the decrease of proliferation ability caused by ectopic expression of PR compared with that of sh-KLF9-control (middle lane) (C). (D) The cell invasion assay demonstrated that sh-KLF9 partly restrained the effect of OEP-PR. For cell invasion assay, sh-KLF9 (right lane) significantly prohibited the role of OEP-PR (middle lane). *, P<0.05. KLF9, Krüppel-like factor 9; PR, progesterone receptor; EC, endometrial cancer.
performed in vivo experiment and found that overexpression of KLF9 inhibited Wnt/β-catenin signaling. Wnt/β-catenin pathway, also known as the canonical Wnt pathway, serve critical roles in cell growth, differentiation, migration, polarity, and death (28). In recent years, dysregulation of Wnt/β-catenin signaling pathway has been recognized as one of the hallmarks of several cancers (29,30), making it become an important target for the development of novel therapeutics for various tumors (31). Accumulation of β-catenin in the cytoplasm followed by its translocation and activation in the nucleus is a central event in the progression of canonical WNT/β-catenin signaling. The abnormal expression or mutations of β-catenin are main reasons leading to dysregulation of Wnt/β-catenin pathway. Our results showed that KLF9 could downregulate β-catenin expression and inhibit β-catenin activity, thus inhibiting the activation of Wnt/β-catenin signaling pathway. However, the involved downstream genes of Wnt/β-catenin pathway are unclear, which needs further researching.

Progesterone functions as a tumor suppressor in the endometrium. A majority of endometrial tumors arise in the setting of excess estrogen unopposed by progesterone (32). Not surprisingly, the expression of PR is gradually lost with progression of EC, thus abrogating the tumor suppressive properties of progesterone. Several mechanisms elucidating PR mediated tumor suppressor have been proposed, including cell cycle arrest, inhibiting proliferation, and activating apoptosis (33,34). We demonstrated that PR could also act through upregulating KLF9, thus inhibiting the initiation and progression of EC.

The present study aimed at disclosing the role of KLF9 in EC, to lay the foundation for the development of more effective therapies. Collectively, we showed that KLF9 could inhibit endometrial carcinogenesis and progression and may serve as a potential target for antineoplastic therapies. We proposed that the axis PR/KLF9/β-catenin could be considered as a novel therapeutic application for EC patients.

Acknowledgments

Funding: This research was supported in part by grants from National Natural Science Foundation of China (81472427 and 81672574), the leading edge technology joint research projects of Shanghai Shenkang Hospital Development Center (SHDC12015110), the Grant (QNRC-2016104) from Jiangsu Provincial Medical Youth Talent, and the Project of Invigorating Health Care through Science, Technology and Education for Jiangsu Provincial Medical Youth Talent.

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The research was carried out in accordance with the Declaration of Helsinki [2013] of the World Medical Association and the study protocol was approved by Research Ethics Committee of Nanjing Medical University. Ethical approval to perform this research was approved by Human Research Ethics Committee of Shanghai General Hospital of Nanjing Medical University (No. 201439), and written informed consent was provided by each patient included in this study.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

5. Pan X, Li D, Huo J, et al. LINC01016 promotes the


29. Kwan HT, Chan DW, Cai PC, et al. AMPK activators suppress cervical cancer cell growth through inhibition of

© Translational Cancer Research. All rights reserved. Transl Cancer Res 2020;9(4):2220-2230 | http://dx.doi.org/10.21037/tcr.2020.03.53


